文献速递临床试验与 GCP

低剂量硫酸亚铁与多糖铁复合物对营养性缺铁性贫血幼儿血红蛋白浓度的影响:一项随机临床试验

Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项双盲优效性随机临床试验纳入80例9至48月龄营养性缺铁性贫血患儿,比较每日一次3 mg/kg元素铁(硫酸亚铁滴剂或多糖铁复合物滴剂)共12周对血红蛋白的影响。12周时硫酸亚铁组血红蛋白升幅更大(差异1.0 g/dL,95%CI 0.4至1.6 g/dL;P<.001),缺铁性贫血完全缓解比例更高(29% vs 6%;P=.04),但多糖铁复合物组腹泻报告更多(58% vs 35%;P=.04)。作者认为营养性缺铁性贫血患儿可考虑每日一次低剂量硫酸亚铁。

要点

  • 9至48月龄营养性缺铁性贫血患儿中,硫酸亚铁12周血红蛋白升幅较多糖铁复合物更大(差异1.0 g/dL;P<.001)。
  • 硫酸亚铁组缺铁性贫血完全缓解比例29% vs 多糖铁复合物组6%(P=.04)。
  • 多糖铁复合物组腹泻报告58% vs 硫酸亚铁组35%(P=.04)。

核心结论

  • 在9至48月龄营养性缺铁性贫血婴幼儿中,与多糖铁复合物相比,硫酸亚铁在12周时使血红蛋白浓度升高更多。
  • 作者认为,营养性缺铁性贫血患儿可考虑每日一次低剂量硫酸亚铁。

研究设计与样本

  • 双盲、优效性随机临床试验,在美国一家三级医院门诊血液科开展,时间为2013年9月至2015年11月,12周随访于2016年1月结束。
  • 纳入9至48月龄、经病史和实验室标准评估为营养性缺铁性贫血的婴幼儿,共随机80例(中位年龄22个月;55%男性;61%西班牙裔白人;每组40例),59例完成试验(硫酸亚铁组28例[70%];多糖铁复合物组31例[78%])。
  • 干预为每日一次3 mg/kg元素铁,分别为硫酸亚铁滴剂或多糖铁复合物滴剂,共12周。

主要发现

  • 从基线至12周,平均血红蛋白由7.9升至11.9 g/dL(硫酸亚铁组)vs 由7.7升至11.1 g/dL(多糖铁复合物组),硫酸亚铁组差异更大,为1.0 g/dL(95%CI 0.4至1.6 g/dL;P<.001),基于线性混合模型。
  • 缺铁性贫血完全缓解的比例硫酸亚铁组更高(29% vs 6%;P=.04)。
  • 中位血清铁蛋白12周内由3.0升至15.6 ng/mL(硫酸亚铁组)vs 由2.0升至7.5 ng/mL(多糖铁复合物组),硫酸亚铁组差异更大,为10.2 ng/mL(95%CI 6.2至14.1 ng/mL;P<.001)。
  • 平均总铁结合力由501降至389 μg/dL(硫酸亚铁组)vs 由506降至417 μg/dL(多糖铁复合物组),硫酸亚铁组差异更大,为-50 μg/dL(95%CI -86至-14 μg/dL;P<.001)。
  • 多糖铁复合物组腹泻报告多于硫酸亚铁组(58% vs 35%;P=.04)。

关键数值与推荐

  • 缺铁性贫血完全缓解定义为12周访视时血红蛋白浓度>11 g/dL、平均红细胞体积>70 fL、网织红细胞血红蛋白当量>25 pg、血清铁蛋白水平>15 ng/mL、总铁结合力<425 μg/dL。
  • 干预剂量为每日一次3 mg/kg元素铁,疗程12周。

临床怎么用

  • 作者认为,营养性缺铁性贫血患儿可考虑每日一次低剂量硫酸亚铁。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Iron-deficiency anemia (IDA) affects millions of persons worldwide, and is associated with impaired neurodevelopment in infants and children. Ferrous sulfate is the most commonly prescribed oral iron despite iron polysaccharide complex possibly being better tolerated. OBJECTIVE: To compare the effect of ferrous sulfate with iron polysaccharide complex on hemoglobin concentration in infants and children with nutritional IDA. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, superiority randomized clinical trial of infants and children aged 9 to 48 months with nutritional IDA (assessed by history and laboratory criteria) that was conducted in an outpatient hematology clinic at a US tertiary care hospital from September 2013 through November 2015; 12-week follow-up ended in January 2016. INTERVENTIONS: Three mg/kg of elemental iron once daily as either ferrous sulfate drops or iron polysaccharide complex drops for 12 weeks. MAIN OUTCOMES AND MEASURES: Primary outcome was change in hemoglobin over 12 weeks. Secondary outcomes included complete resolution of IDA (defined as hemoglobin concentration >11 g/dL, mean corpuscular volume >70 fL, reticulocyte hemoglobin equivalent >25 pg, serum ferritin level >15 ng/mL, and total iron-binding capacity <425 μg/dL at the 12-week visit), changes in serum ferritin level and total iron-binding capacity, adverse effects. RESULTS: Of 80 randomized infants and children (median age, 22 months; 55% male; 61% Hispanic white; 40 per group), 59 completed the trial (28 [70%] in ferrous sulfate group; 31 [78%] in iron polysaccharide complex group). From baseline to 12 weeks, mean hemoglobin increased from 7.9 to 11.9 g/dL (ferrous sulfate group) vs 7.7 to 11.1 g/dL (iron complex group), a greater difference of 1.0 g/dL (95% CI, 0.4 to 1.6 g/dL; P < .001) with ferrous sulfate (based on a linear mixed model). Proportion with a complete resolution of IDA was higher in the ferrous sulfate group (29% vs 6%; P = .04). Median serum ferritin level increased from 3.0 to 15.6 ng/mL (ferrous sulfate) vs 2.0 to 7.5 ng/mL (iron complex) over 12 weeks, a greater difference of 10.2 ng/mL (95% CI, 6.2 to 14.1 ng/mL; P < .001) with ferrous sulfate. Mean total iron-binding capacity decreased from 501 to 389 μg/dL (ferrous sulfate) vs 506 to 417 μg/dL (iron complex) (a greater difference of -50 μg/dL [95% CI, -86 to -14 μg/dL] with ferrous sulfate; P < .001). There were more reports of diarrhea in the iron complex group than in the ferrous sulfate group (58% vs 35%, respectively; P = .04). CONCLUSIONS AND RELEVANCE: Among infants and children aged 9 to 48 months with nutritional iron-deficiency anemia, ferrous sulfate compared with iron polysaccharide complex resulted in a greater increase in hemoglobin concentration at 12 weeks. Once daily, low-dose ferrous sulfate should be considered for children with nutritional iron-deficiency anemia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01904864.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Powers JM, Buchanan GR, Adix L, et al. Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial. JAMA. 2017. PMID: 28609534. doi:10.1001/jama.2017.6846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。